



Efficient characterization of multiple binding sites of small molecule imaging ligands on amyloid-beta, tau and alpha-synuclein

Jens Sobek¹ · Junhao Li² · Benjamin F. Combes³ · Juan A. Gerez⁴ · Martin T. Henrich^{5,6} · Fanni F. Geibl^{5,6} · Peter R. Nilsson⁷ · Kuangyu Shi⁸ · Axel Rominger⁸ · Wolfgang H. Oertel^{5,6} · Roger M. Nitsch³ · Agneta Nordberg⁹ · Hans Ågren² · Ruiqing Ni^{3,8,10} 

Received: 16 March 2024 / Accepted: 17 June 2024
© The Author(s) 2024

Abstract

Purpose There is an unmet need for compounds to detect fibrillar forms of alpha-synuclein (α Syn) and 4-repeat tau, which are critical in many neurodegenerative diseases. Here, we aim to develop an efficient surface plasmon resonance (SPR)-based assay to facilitate the characterization of small molecules that can bind these fibrils.

Methods SPR measurements were conducted to characterize the binding properties of fluorescent ligands/compounds toward recombinant amyloid-beta ($A\beta$)₄₂, K18-tau, full-length 2N4R-tau and α Syn fibrils. In silico modeling was performed to examine the binding pockets of ligands on α Syn fibrils. Immunofluorescence staining of postmortem brain tissue slices from Parkinson's disease patients and mouse models was performed with fluorescence ligands and specific antibodies.

Results We optimized the protocol for the immobilization of $A\beta$ ₄₂, K18-tau, full-length 2N4R-tau and α Syn fibrils in a controlled aggregation state on SPR-sensor chips and for assessing their binding to ligands. The SPR results from the analysis of binding kinetics suggested the presence of at least two binding sites for all fibrils, including luminescent conjugated oligothiophenes, benzothiazole derivatives, nonfluorescent methylene blue and lansoprazole. In silico modeling studies for α Syn (6H6B) revealed four binding sites with a preference for one site on the surface. Immunofluorescence staining validated the detection of pS129- α Syn positivity in the brains of Parkinson's disease patients and α Syn preformed-fibril injected mice, 6E10-positive $A\beta$ in arc $A\beta$ mice, and AT-8/AT-100-positivity in pR5 mice.

Conclusion SPR measurements of small molecules binding to $A\beta$ ₄₂, K18/full-length 2N4R-tau and α Syn fibrils suggested the existence of multiple binding sites. This approach may provide efficient characterization of compounds for neurodegenerative disease-relevant proteinopathies.

Keywords Alpha-synuclein · Amyloid-beta · Binding sites · In silico · Surface plasmon resonance · Tau

✉ Ruiqing Ni
ruiqing.ni@uzh.ch

¹ Functional Genomics Center, University of Zurich & ETH Zurich, Zürich, Switzerland

² Department of Physics and Astronomy, Uppsala University, Uppsala, Sweden

³ Institute for Regenerative Medicine, University of Zurich, Wagistrasse 12, 8952 Zürich, Switzerland

⁴ Laboratory of Physical Chemistry, Department of Chemistry and Applied Biosciences, ETH Zurich, Zürich, Switzerland

⁵ Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany

⁶ Department of Neurology, Philipps-University Marburg, Marburg, Germany

⁷ Division of Chemistry, Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden

⁸ Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

⁹ Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

¹⁰ Institute for Biomedical Engineering, University of Zurich & ETH Zurich, Zürich, Switzerland

Introduction

Neurodegenerative diseases represent a tremendous unmet clinical need. A common feature of these diseases is the abnormal cerebral accumulation and spreading of pathological protein aggregates, which affect selective vulnerable circuits in a disease-specific pattern [1]. Alzheimer's disease (AD) is pathologically characterized by amyloid- β ($A\beta$) plaques and neurofibrillary tangles of hyperphosphorylated tau. Other tauopathies include frontotemporal dementia with 4R and 3R tau, progressive supranuclear palsy (PSP) with 4R tau, and corticobasal degeneration (CBD) with 3R tau accumulation [2]. α -Synucleinopathy is characterized by the accumulation of alpha-synuclein (α Syn) in Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy (MSA). The use of positron emission tomography (PET) with $A\beta$ and tau imaging ligands has facilitated the early/differential diagnosis of AD [3].

Currently, there is an unmet clinical need for PET ligands for 4-repeat tau and α Syn aggregates to assist in diagnostic and clinical outcome evaluations. Several imaging ligands are currently in the pipeline, e.g., [^{18}F]ACI-12589 [4], [^{18}F]F0502B [5], [^{11}C]MODAG-001 [6], [^{18}F]SPAL-T-06 [7] and [^{18}F]UCB-2897 (NCT05274568). Optical imaging ligands have been developed and applied in mechanistic and treatment studies using animal models recapitulating amyloidosis/tauopathy/ α -synucleinopathy. Several imaging ligands, such as BTA-1, methoxy-X04, BF-158, PBB5, luminescent conjugated oligothiophenes (LCOs), BODIPY derivatives and fluorescently labeled antibodies, have been used for two-photon and diffuse optical imaging [8–15]. A number of experimental techniques, including fluorescence assays, radioligand competition assays [16–19], nuclear magnetic resonance spectroscopy of α Syn [20, 21], and cryogenic electron microscopy (cryo-EM) [22, 23], have been used to investigate interactions between ligands and $A\beta$ peptides [24–26] and have demonstrated multiple ligand binding sites. In silico studies have also often been applied to study the interactions between ligands and proteinopathies/fibrils [27–31].

The surface plasmon resonance (SPR) assay is the method of choice for studying the kinetics of interactions for a wide range of molecular systems and has been widely used in pharmaceutical/biosensing/biomolecular research [32, 33]. SPR has been more commonly used for detecting $A\beta$ and tau monomers in biological samples, such as blood or cerebrospinal fluid, as diagnostic biomarkers [34–37]. It has also been used to investigate $A\beta$ elongation, aggregation dynamics [38, 39] and interactions with aggregation inhibitors [40–43]. A few studies have reported the SPR of α Syn fibrils [44–48], tau fibrils [49–51], and $A\beta$ fibrils [51, 52].

A general problem of SPR measurements of small molecule ligand binding to immobilized fibrils is the large molar mass ratio (small molecule compound: < 1000 Da, fibrils > 1 MDa), which requires high surface densities to achieve sufficient signal intensity. This situation is partly improved by the large number of binding sites at the protein complexes leading to higher stoichiometric binding ratios. In a typical SPR experiment, ligand solutions in the concentration range of approximately $1/10$ of K_D and $10 \times K_D$ are injected into the flow cell system of the instrument. In the case of low-affinity (μM) binders, the injection of high nM or μM ligand solutions often leads to strong adsorption of positively charged and/or hydrophobic compounds, including the dyes investigated, to the negatively charged chip surface, which impairs data quality. To overcome problems with unspecific adsorption, a suitable chip surface had to be found for each combination of fibril and dye. Another problem is artifacts of unknown origin that disturb the sensorgram characteristics and, in some cases, render data evaluation impossible.

Here, we optimized SPR protocols to determine the binding kinetics of small molecules (imaging ligands and nonfluorescent compounds) on $A\beta_{42}$, K18-tau, full-length 2N4R tau and α Syn fibrils. We further examined the binding sites of fluorescence ligands on α Syn fibrils by in silico modeling and immunofluorescence staining in postmortem human brain tissues from patients with PD and from preformed fibril (PFF)-injected mouse models.

Materials and methods

Chemicals and antibodies

Detailed information on the chemicals and antibodies used in the study was provided in STables 1 and 2. The excitation and emission spectra of the fluorescence-emitting compounds are summarized in STable 1.

Recombinant $A\beta_{42}$, K18-tau, full-length 2N4R tau and α Syn fibril production, characterization and detection by fluorescence ligands

Recombinant $A\beta_{42}$, K18-tau, full-length 2N4R tau (441 aa) and α Syn were expressed [53, 54] and measured for binding with fluorescent ligands [55] as described previously (details in the [supplementary material](#)).

Surface plasmon resonance assay

SPR measurements were conducted in HEPES-buffered saline (HBS, Teknova, USA) buffer at 20°C using Biacore instruments T200 and S200 (Cytiva, Uppsala, Sweden). $A\beta_{42}$, tau, and α Syn recombinant fibrils were immobilized

in the flow cell of sensor chips produced by Xantec (Düsseldorf, Germany) and Cytiva by coupling fibril amine groups to sulfo-N-hydroxysuccinimide (sulfo-NHS)-activated carboxylic acid groups on the chip surface. Since no nonbinding fibril(s) were available, the reference flow cell remained empty. Different chip surfaces, including the carboxymethylated dextran surface CM5 (Cytiva, Sweden), the carboxymethyl dextran hydrogel surface CMD200M, the linear polycarboxylate hydrogel surface HC30M and HC1500M, the linear polycarboxylate hydrogel (reduced charge) surface HLC30M, and the zwitterionic hydrogel surface ZC150D (all from Xantec, Germany), were tested to obtain a high immobilization density and low nonspecific adsorption of ligands. All steps for surface preparation and immobilization were conducted at a flow rate of 5 $\mu\text{L}/\text{min}$. The surface carboxylic acid groups were activated with 0.2 M sulfo-NHS and 0.1 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, Xantec) (CM5 and CMD200M: 0.05 M) in 5 mM 2-(N-morpholino)ethanesulfonic acid (MES buffer, abcr Swiss AG, Switzerland) at pH 5.0 for 550 s (CM5 and CMD200M: 180 s) using 5 mM MES (pH 6.5) as the running buffer. K18-tau and αSyn fibrils were diluted to 2.5–10 μM in 5 mM acetate buffer (Fisher Scientific, Switzerland) at pH 4.5 and coupled for 750 s at a flow rate of 5 $\mu\text{L}/\text{minute}$ on all surfaces except for ZD150D. Surfaces were blocked with 1 M ethanolamine (Xantec, Germany) for 500 s. On the ZC150D chip, K18-tau, αSyn and $\text{A}\beta_{42}$ were immobilized at 2.5–10 μM in 5 mM MES, pH 6.5, for 750 s to a surface activated with 0.5 M EDC and 0.1 M sulfo-NHS for 600 s in 5 mM MES, pH 6.5. Finally, the surface was blocked with 1 M glycine in 10 mM MES, pH 6.5.

Binding kinetics were measured after a stabilization period of a few hours, which was necessary due to a slight decrease in the baseline, presumably caused by the slow dissociation of the fibrils. The immobilized fibrils were stable for a few days. Kinetic constants for binding were determined by injection of a dilution series of 5–8 concentrations of ligand in HBS buffer at a flow rate of 30 $\mu\text{L}/\text{minute}$ in duplicate ("full kinetics"). Since no regeneration conditions were found that did not lead to decomposition of the fibrils, single cycle kinetics [56] were measured in cases of slow dissociation by consecutive injections of 5 ligands followed by a dissociation period of 10 min.

The data was evaluated using BiaEvaluate v2.03 software (Cytiva, Sweden). Binding kinetics were analyzed globally using different kinetic models, including 1 + 1, a sum of two exponentials model ("heterogeneous ligand" in terms of BiaEvaluate, sum2exp), and a sum of three exponentials model (sum3exp) that was created using the script editor of the software. The software does not allow the creation of higher-order kinetic models.

In silico modeling and calculations

αSyn fibrils were obtained from previous studies (PDB codes: 6H6B [57, 58] and 2N0A [29]). The protein preparation wizard module in the Schrödinger suite (V. 2021–3, Schrödinger LLC, New York, U.S.A.) was used to add hydrogen atoms and determine the protonation states of the ionizable residues. The initial structures of the tested compounds were drawn at the Maestro interface and optimized using the Ligprep module (Schrödinger Release 2021–3: LigPrep, Schrödinger, LLC, New York, U.S.A.). The Glide module was used for docking, in which we used normal inner and outer box sizes of 10 and 20 Å, respectively [59, 60]. The standard precision mode was used for dockings, while other settings were left as default in Glide. The top 1 scored binding pose of each ligand– αSyn complex was subjected to molecular dynamics (MD) simulations. All MD simulations were carried out for 100-ns production with the OPLS-4 force field [61] using the Desmond module. In each simulation, the protein–ligand complex was centered into an orthorhombic box with a boundary buffer of 12 Å, and ~24,000 TIP3P water [62] molecules and counterions were added to neutralize the system. Additional Na^+ and Cl^- were added to reach a 0.15 M salt concentration. Before the production simulations, the system was energy minimized and equilibrated with a Nose–Hoover chain thermostat (300.0 K) [63] and Martyna-Bobias-Klein barostat (1.0 atm) [64] using the default protocol implemented in Desmond. The molecular mechanics (MM)/generalized born solvent accessibility (GBSA) [65] binding free energy for each ligand was averaged from a total of 200 snapshots evenly extracted from the 100-ns trajectories. The Prime module [Schrödinger Release 2021–3: Prime, Schrödinger, LLC, New York, 2021.] was used for the MM/GBSA calculations. The protein–ligand complexes were refined and optimized using the OPLS4 force field with the variable dielectric surface generalized born (VSGB) continuum solvation model [66]. For the minimization, the residues within 5 Å of the ligand were included. After that, the MM/GBSA method implemented in the Prime module was used to rescore the binding poses. Root-mean-square deviation (RMSD) analysis of the average distance between a group of atoms (e.g., backbone atoms of the four binding sites on αSyn) was performed.

Postmortem human brain tissue

Two PD patients, each with a clinical diagnosis confirmed by pathological examination of Lewy bodies (Braak LB 6, without tau and $\text{A}\beta$), were included in this study (detailed information in Table 1). Paraffin-embedded autopsied brain tissues from the medulla oblongata and cerebellum with

Table 1 Results of SPR measurements of α Syn fibrils and $A\beta_{42}$ fibrils and K18 and full-length 2N4R tau fibrils

Fibril	Analyte	Surface	Surface density/ RU	$k_a/M^{-1} s^{-1}$	k_d/s^{-1}	K_D/M	RU (max)	χ^2
α Syn	HS-169	CMD200M	2940	2.88E+05	2.54E-03	8.8E-09	16.3	0.60
				1.45E+05	4.18E-02	2.89E-7	45.4	
	HS-84	CMD200M	3400	1.161E+04	5.45E-06	4.78E-10	22.5	0.59
				1.115E+06	6.02E-02	5.40E-08	42.2	
	h-FTAA	CMD200M	3400	1.62E+05	2.86E-03	1.77E-08	2.8	0.05
				1.11E+05	5.82E-02	5.23E-07	19.3	
q-FTAA	CM5	2940	9.07E+05	1.52E-02	1.67E-07	26.7	0.99	
			1.53E+03	7.05E-04	4.61E-07	60.9		
MB	CMD200M	3400	4.72E+05	8.34E-01	1.77E-06	39.0	0.06	
			4.57E+02	1.71E-02	3.75E-05	107.0		
K18-tau	HS-84	CMD200M	8280	4.89E+03	2.21E-03	4.52E-07	35.3	0.07
				3.59E+06	6.33E+0	1.76E-06	33.4	
	q-FTAA	CMD200M	8280	4.89E+02	3.14E-03	6.419E-06	47.9	0.16
				2.798E+03	5.85E-02	2.092E-05	32.1	
	h-FTAA	HC1500M	9010	5.32E+01	1.49E-04	2.81E-06	5968	0.19
				2.70E+02	3.02E-02	1.12E-04	900	
2N4R-tau	HS-169	ZC150D	2900	6.78E+01	1.64E-05	2.41E-07	2216	2.23
				1.12E+04	8.09E-03	7.23E-07	67.6	
	Lan	ZC150D	2900	1.15E+02	1.74E-04	1.51E-06	2682	0.09
$A\beta_{42}$	HS-169	ZC150D	1770	5.03E+03	4.26E-02	8.47E-06	93.6	
				1.20E+02	1.67E-05	1.39E-07	641	0.49
	Lan	ZC150D	1770	5.79E+02	1.05E-02	1.82E-05	367.3	
				9.47E+02	1.63E-04	1.72E-07	383	0.07
			3.49E+03	3.81E-02	1.09E-05	98.9		

$k_a/M^{-1} s^{-1}$ rate constants of association; k_d/s^{-1} rate constants of dissociation; K_D/M equilibrium dissociation constant. The calculations were performed using a sum2exp kinetic model; $RU(max)$ response units at steady state; *Lan* lansoprazole; *MB* methylene blue

high α Syn inclusion accumulation were obtained from the Netherlands Brain Bank (NBB), Netherlands (Table 2).

Animal models

Two transgenic arcA β mice overexpressing the human APP695 transgene harboring the Swedish (K670N/M671L) and Arctic (E693G) mutations under the control of the prion protein promoter and two age-matched nontransgenic littermates of both sexes (18 months of age) [67, 68] (Table 2). Two transgenic MAPT P301L mice overexpressing human 2N/4R tau under the neuron-specific Thy1.2 promoter (pR5 line, C57B6. Dg background) and two age-matched nontransgenic littermates of both sexes (18 months of age) [69] (Table 2). For the α Syn PFF mouse model, two male C57BL/6 J mice (Charles River, Sulzfeld, Germany), 8 weeks old at the beginning of the experiment, were used (Table 2). Animals were housed in individually ventilated cages inside a temperature-controlled room under a 12-h dark/light cycle with ad libitum access to food and water. For induction of α Syn pathology, a total volume of 550 nL of α Syn PFFs

(concentration 2.5 μ g/ μ L) was stereotactically injected into the pedunclopontine nucleus (PPN) or substantia nigra pars compacta (SNc) as previously described [70]. Twelve weeks postinjection, the mice were sacrificed, and tissue was prepared for immunohistochemical analysis. arcA β , pR5 and PFF injected mice were perfused under ketamine/xylazine (75/10 mg/kg or 50/4.5 mg/kg body weight, *i.p.* bolus injection) with ice-cold 0.1 M PBS (pH 7.4) and 4% paraformaldehyde (PFA) in 0.1 M PBS (pH 7.4). After perfusion, the mice were decapitated, and the brains were quickly removed and fixed for 1 or 3 days in 4% PFA (pH 7.4) and 3 days in 30% sucrose solution. The brains were then frozen on dry ice and stored at -80 °C until sectioning.

Ex vivo immunofluorescence and microscopy

The details on the antibodies and ligand concentrations are described in STable 1. 2. Human paraffin-embedded brain sections (3 μ m) were deparaffinized and rehydrated prior to antigen retrieval step (citrate buffer pH 6.0) in a microwave for 20 min at 98 °C. The sections were then costained

Table 2 Information on brain tissue samples from patients with Parkinson's disease and animal models

Postmortem human brain sample		Sex	Age (y)	PM delay (h)	Braak tau	Amyloid- β	Braak LB	Diagnosis	Region
No									
1		M	61	7.5	1	O	6	PD	MO
2		M	65	4.8	0	O	6	PD	MO
Mouse brain sample					Number of mice	Sex	Age (m)	Region imaged	
Model									
	α Syn PFF-injected mice				2	M	5	CeA, NAc, PPN, PAG	
	arcA β mice				2	M/F	18	Ctx	
	pR5 mice				2	M/F	18	Hip	
	Non-transgenic littermate mice				4	M/F	18	Ctx, Hip	

Ctx cortex; *CeA* central amygdala; *LB* Lewy body; *MO* medulla oblongata; *NAc* nucleus accumbens; *PD* Parkinson's disease; *PPN* pedunculopontine nucleus; *PAG* periaqueductal gray; Two non-transgenic littermate mice for arcA β and pR5 mice, respectively. For the α Syn PFF-injected mouse model, the injection of PFF in the brain was performed at 8 weeks of age, with the endpoint at 20 weeks of age (5 months)

with anti- α Syn (phospho-S129, pS129) antibody plus fluorescent secondary antibody. Ligands were incubated after secondary antibody incubation for 30 min. Sections were counterstained using 4',6-diamidino-2-phenylindole (DAPI). Mouse brains were embedded in tissue freezing media (OCT Compound, Tissue Tek, USA) and cut into 30–40 μ m thick consecutive coronal sections using a cryostat microtome (CM3050 S, Leica, Germany). All sections spanning the complete rostrocaudal extent of the brain were kept in the correct order and stored at 4 °C in cryoprotect solution (1:1:3 volume ratio of ethylenglycol, glycerol and 0.1 M PBS) until further processing [71]. Anti- α Syn pS129 antibodies, anti-phospho-tau antibodies (AT-8, AT-100), or anti-A β ₁₋₁₆ antibody 6E10 plus fluorescent secondary antibody were used as previously described on brain slices from α Syn PFF-injected mice, arcA β mice [72], and pR5 mice [55]. Ligands were incubated with secondary antibody for 30 min. Sections were counterstained with DAPI. The brain sections were imaged at 20 \times magnification using an Axio Observer Z1 microscope (whole brain slide scanner) and at 63 \times magnification using a Leica SP8 confocal microscope (Leica, Germany) for colocalization. It took approximately 1–1.5 h to acquire the tilted human brain slices by a slide scanner in our experiment (20 \times). The time varied depending on the size of the sample. Lambda scans were performed using a Leica SP8 confocal microscope for the emission spectrum of the ligands on the staining as previously described to validate the signal [55]. The images were analyzed using Qupath [73] and Fiji [74] (NIH, U.S.A.). Colocalization analysis of the confocal microscopy images (probe and antibody channels) was performed by using Fiji, and Manders' coefficients (M1, M2) were computed.

Results

In vitro fluorescence binding assays in recombinant fibrils

We produced A β ₄₂, K18-tau, full-length 2N4R tau and α Syn fibrils using bacterially produced recombinant monomers. During the processing of K18-tau, full-length 2N4R tau and α Syn after each step, an aliquot was taken, and at the end, identity was verified by SDS-PAGE (SFig. 1). The monomers were validated using western blotting, and the fibrils were validated using thioflavin T assays and TEM (Figs. 1, 2 and 3).

SPR measurements of ligand binding to fibrils

The detailed protocol for the SPR measurements was described in the supplementary results section. Surfaces were tested to obtain sufficient immobilization of different




Fig. 1 Characterization of ligand binding on recombinant alpha-synuclein fibrils. **a-g** Chemical structures of q-FTAA, h-FTAA, HS-84, HS-169, PBB5, lansoprazole and methylene blue. **h** Western blot of αSyn using anti-αSyn antibody, Syn211; **i** TEM of αSyn fibrils; **j-**

o Sensorgrams of q-FTAA(**j**), h-FTAA(**k**), HS-169(**l**), HS-84(**m**), PBB5(**n**), and methylene blue(**o**), binding to αSyn fibrils. The black line represents the experimental data, and the red line represents the fitted curve




Fig. 2 Characterization of ligand binding on recombinant K18-tau and full-length 2N4R tau fibrils. **a** Western blot of K18-tau and full-length 2N4R tau using anti-Tau(RD4) antibody, 1E1/A6; **b** TEM of K18-tau and full-length 2N4R tau fibrils; **c-g** Sensorgrams of HS-84(**c**), methylene blue(**d**), q-FTAA(**e**), h-FTAA(**f**), and HS-169(**g**)

binding to K18-tau fibrils. (**h-j**) Sensorgrams of HS-84 (**h**), HS-169 (**i**), and lansoprazole (**j**) binding to full-length 2N4R tau fibrils. The black line represents the experimental data, and the red line represents the fitted curve

fibrils and low nonspecific adsorption of the ligands/drugs. The best surface was chosen for different fibrils in the kinetic evaluation experiments, with the results shown in Table 1; In most cases, only one surface fulfilled the requirements for a valid measurement. For almost all ligands, the analysis of sensorgrams with a 1 + 1 kinetic model revealed poor fits due to high values of the least square error (χ^2) and a nonrandom distribution of residuals. Kinetic models of higher order, including the sum2exp and sum3exp models,

are better suited, which leads to good fits (Figs. 1, 2 and 3, Table 1). Kinetic data obtained with the sum2exp model revealed that in most cases, binding occurs in the high-nM to low- μ M range. Only a few interactions of α Syn fibrils with HS-84 and the minor components of HS-169 and h-FTAA have affinities in the lower nM range.

Diffusion-controlled reactions of small molecules have rate constants on the order of $10^9 \text{ M}^{-1} \text{ s}^{-1}$. However, from experience with the kinetics of small molecule binding




Fig. 3 Characterization of ligand binding on recombinant $A\beta_{42}$ fibrils. **a** Western blot of $A\beta_{42}$ using the monoclonal anti- β -amyloid antibody BAM-10; **b** TEM image of $A\beta_{42}$ fibrils; **c-e** Sensorgrams of

HS-169, HS-84 and lansoprazole binding to $A\beta_{42}$ fibrils. The black line represents the experimental data, and the red line represents the fitted curve

to proteins, fast association constants are in the range of 10^5 – 10^6 $M^{-1} s^{-1}$ and above. Values as low as 10^3 $M^{-1} s^{-1}$ and lower are considered slow. We found that some ligands bind to fibrils very slowly, as indicated by small association rate constants lower than 10^3 $M^{-1} s^{-1}$. This was observed for the interaction of q-FTAA with α Syn and K18-tau fibrils (Figs. 1 and 2); h-FTAA with K18-tau fibrils (Fig. 2); and for HS-169 and lansoprazole with both full-length 2N4R tau and $A\beta_{42}$ fibrils (Figs. 2 and 3), respectively. Furthermore, we observed a number of artifacts of unknown origin impairing data quality, including large jumps (not shown) and a decrease in the signal during injection for α Syn/PBB5 (Fig. 1n).

It is noted that there is a difference between full kinetics and single-cycle (sc) kinetics measurements. Full kinetics measurements are preferred since they have the advantage of a larger number of full injection-dissociation cycles that can be conducted resulting in more data for fitting. Sc kinetics are usually applied when dissociation is slow for the analyte to be dissociated completely (back to baseline) since only then can a new (full) cycle be started without compromising the following measurement. In Biacore instruments, sc

kinetics are limited to 5 injections and a single dissociation phase.

In silico modeling demonstrated multiple binding sites for LCOs on α Syn fibrils

Here, we used the 6H6B structure from the recombinant α Syn fibril, which is assembled in paired helical fibril form. From the molecular docking studies of HS-169, HS-84, p-FTAA, and q-FTAA, we identified four binding sites on the α Syn fibril (6H6B, Fig. 4a, b), denoted sites 1–4. The salt bridge between E57 and H50 and the van der Waals interactions between the shallow hydrophobic residues (G51, A53, and V55) stabilize the paired fibrils in 6H6B. Site 3 is a core site inside the fibril and can be easily accessed when a limited number of molecules are used in the modeling, which might not be easily accessible in real situations. We carried out a 100-ns MD simulation for the binding of each ligand at each site, resulting in 20 trajectories with a total length of 2 μ s. The ligands HS-169, HS-84, p-FTAA and q-FTAA are negatively charged; therefore, the binding affinities at site 4, which is a positively charged site, are more favorable




Fig. 4 In silico modeling of the binding sites of HS-169, HS-84, h-FTAA, p-FTAA and q-FTAA on the 6H6B α Syn structure. **a** Four binding sites (S1-S4) on alpha-synuclein fibrils; the red circle indicates the location of site 4; **b** Zoomed-in view of h-FTAA binding to

site 4. **c** MM/GBSA calculation of free energy indicating that site 4 is preferred by HS-169, HS-84, h-FTAA, p-FTAA and q-FTAA. **d-g** RMSD analysis of the ligands binding to 4 binding sites (S1-S4)

than those at site 3 (Fig. 4c). In line with the docking studies, the ranking of binding free energies indicates that HS-169 and HS-84 strongly bind to site 4, followed by p-FTAA, q-FTAA and h-FTAA. These compounds are rich in hydrogen acceptors/donors and form stable hydrogen bonds with a cluster of positively charged residues K43, K45, H50, and K58 (Fig. 4c). The ligand RMSD to the initial conformation, usually used to estimate the stability of the binding, shows a deviation larger than 8 Å, which indicates that the ligand has moved away from the original binding site (Fig. 4d-g). From this point of view, the stability of the binding sites can be ranked as $S4 \approx S3 > S2 > S1$ for the binding of the five investigated ligands. We also note that the FTAA compounds were more stable in the core site 3 than in the dimer interface site 4. The positions of the acetate groups on the two neighbouring thiophene moieties of the centre thiophene appear to distinguish the stabilities of FTAA (3''-yl acetate) and HSs (4''-yl acetate) in the interior core site 3 (SFig. 2). Additional *in silico* modelling was performed using the 2N0A α Syn structure. Four binding sites for DCVJ were demonstrated on the 2N0A α Syn structure [29]. Here, we found a preference of these ligands for core site 3 using the 2N0A α Syn structure (SFIGs. 3).

Validation using immunofluorescence staining of postmortem human brain tissue and mouse models

We investigated the ligand detection of α Syn inclusions using an antibody that recognizes α Syn phosphorylated at serine 129 (pS129), as this epitope is a hallmark of Lewy bodies. We showed that ligands (h-FTAA, q-FTAA, and HS-169) were bound to pS129-positive α Syn inclusions in medulla oblongata tissue slices from two patients with PD (Figs. 5a-d, i). Colocalization of different ligands to both Lewy neurites and Lewy bodies was observed. Interestingly, the pS129 antibody (AB5336P) we used in the study appeared to detect the rim of the α Syn deposits, whereas q-FTAA detected the whole structure of the α Syn deposits (Figs. 5d). This difference is reflected by the relatively low coefficient of overlap between the q-FTAA and pS129 staining results (STable 3).

Next, we evaluated the effects of HS-169 and HS-84 on α Syn-PFF-injected mice at 12 weeks after injection into the PPN. A positive pS129 signal was detected in the ChAT-positive cholinergic PPN neurons of α Syn-PFF-injected mice (Fig. 5e, j). Colocalization of the ligands (HS-169 and HS-84) with the pS129 signal was observed in the PPN and periaqueductal gray of PPN-injected mice (Figs. 5e-g) and in the SNc as well as in the nucleus accumbens of the SNc-injected mice (Fig. 5h, k). The somatic pS129-positive α Syn

aggregates appeared to be better stained by ligands than the neuritic pS129-positive α Syn aggregates (Fig. 5g).

To validate the detection of A β or tau pathology, we studied the binding of the aforementioned ligands to the brains of transgenic mice with A β or tau pathology. We chose transgenic mouse models to study A β or tau pathology since the brain tissue from AD patients commonly shows the coexistence of these two pathologies. Tau mainly accumulates in the cortex and hippocampus of pR5 mice. Immunofluorescence staining of coronal brain tissue sections from pR5 and nontransgenic mice costained with an anti-phospho-tau AT-8 antibody in the cortex and hippocampus confirmed the presence of PBB5 in tau inclusions (Fig. 6a-c). AT-100 antibody (mature phospho-tau) staining for PBB5 was performed on brain tissue slices from pR5 mice, and the results further validated the results (Fig. 6a, b).

We assessed ligand detection of A β deposits in brain tissue slices from arcA β mice using 6E10. arcA β mice develop A β pathology affecting both the brain parenchyma and vasculature from 6 months of age [67]. Immunofluorescence staining performed on coronal brain tissue sections from arcA β and nontransgenic mice with ligands (h-FTAA, q-FTAA, and HS-169) costained with 6E10 (anti-A β ₁₋₁₆) antibody further confirmed the detection of parenchymal A β deposits in the cortical regions (Fig. 6d-g).

Discussion

In the present work, SPR was used to characterize the binding of imaging ligands and small molecules to A β ₄₂, K18-tau, full-length 2N4R-tau and α Syn fibrils. The measured sensorgrams could not be evaluated by fitting a simple 1 + 1 kinetic model, suggesting that the binding kinetics are complex. Kinetic models of higher order, including the sum2exp and sum3exp models, were better suited for fitting the data. Based on the evident assumption of independent binding of a ligand to different sites, each interaction is characterized by a specific association and dissociation rate constant and its relative weight. In this case, the order of the fit model corresponds to the number of binding sites. Models of higher order, the sum2exp and, for some cases, the sum3exp model, considerably improved the fit results assessed by the least square error (χ^2) and the distribution of residuals (Table 1, Figs. 1, 2 and 3).

However, it must be noted that fitting with the sum3exp model introduces considerable uncertainty to the kinetic constants due to the large number of initial parameters (k_a , k_d , and RU_{max} for each additional interaction, plus (optional) a parameter for the bulk response (RI) and a mass transfer coefficient), which can cause the fit routine to become stuck in local minima. This can be shown by repeating a fit with




Fig. 5 Confocal imaging of alpha-synuclein inclusions in brain tissue sections from PD patients and α Syn PFF-injected mice. **a–d** Colocalization of the Alexa488-anti- α Syn phosphor S129 antibody pS129 (green) with h-FTAA (yellow), HS-169 (cyan), and q-FTAA (magenta) in the medulla oblongata of PD patients (whole region image in **i**). α Syn-positive Lewy neurites (*) and Lewy bodies (arrowhead). **e–f**, **j** pS129-positive inclusions in ChAT-positive neurons (yellow) in the pedunculopontine nucleus (PPN) of α Syn-

PFF-injected mice, with whole-brain images in **j**. **(f)** Colocalization of pS129-positive inclusions (green) with HS-169 (cyan) in the periaqueductal gray (PAG). **g**, **h** pS129-positive inclusions in TH-positive neurons (yellow) in the substantia nigra pars compacta (SNc) of α Syn-PFF-injected mice with whole-brain images in **k**. **(h)** Colocalization of pS129-positive inclusions (green) with HS-84 (red) in the nucleus accumbens (NAc)




Fig. 6 Confocal imaging of ligands with tau and amyloid-beta in mouse models. **a–c** Colocalization of tau staining by Alexa488-AT8 (red), Alexa488-AT100 (magenta) with h-FTAA (green), PBB5 (yellow), and HS-169 (cyan) in the hippocampus of pR5 tau mice; **d–g**

colocalization of the anti- $A\beta_{1-16}$ antibody Alexa488-6E10 (green) with HS-84 (red), h-FTAA (yellow), q-FTAA (magenta), and HS-169 (cyan) in the cortex of arcA β mice. Nuclei were counterstained using DAPI (white)

a single parameter being changed by an order of magnitude, a procedure that often does not reproduce the initial fit. Extensive tests with the sum3exp model revealed that the fit results show low resistance to changes in the initial parameters. For this reason, we limited the evaluation to the sum2exp model, although the residuals showed a more random distribution without a recognizable pattern, and χ^2 was often much lower when the sum3exp model was applied and refrained from publishing fit results.

The number of exponentials needed to fit a sensorgram does not necessarily coincide with the number of binding sites identified in modeling calculations. In our interpretation, this represents the lower limit since some interactions may not be resolved due to the similarity of rate constants and the general limitation of SPR data quality. Therefore, we state that the results from the SPR measurements are in agreement with the modeling calculations and clearly support the notion of the existence of multiple binding sites in the fibrils even though their number cannot be precisely determined.

The binding of different ligands on the various sites of these fibrils with abnormal ligand binding cavities was also evaluated by free energy calculations to rank the affinities. In silico modeling suggested 4 binding sites on α Syn with a

preference for certain binding pockets of different molecules (Fig. 4), which can be classified by the extent of solvent exposure. Sites S1 and S2 are similar due to the largest exposure to solvent, with similar dynamics for most of the docked ligands, of which the ligands left the original site quickly. Site S3 is the interior core site, which has the least solvent exposure, followed by site S4, which is located at the dimer interface. The binding of FTAA ligands in sites S3 and S4 were stable for the FTAA ligands during the MD simulations. Therefore, in view of the ligand fluctuations, molecular dynamics support the existence of similar binding sites as the binding sites from SPR study. However it is noted that SPR sensorgrams generally suffer from low temporal resolution (10–40 data points/s). For this reason, fitting with more than 2 exponentials does not yield reliable results. In contrast, in time-resolved fluorescence measurements by single-photon counting, millions of photons are typically collected, which allows 3 or even 4 exponentials to be fitted with high significance. This is not possible for SPR data analysis.

The stability of the binding sites identified by docking was further evaluated by MD simulations and binding free energy calculations. These studies provide atomic details and identify key amino residues for the interaction between

ligands and fibrils. Here, an induced-fit mechanism of ligand binding, e.g., the enlargement of a narrow cleft in the protofibril when a large and planar ligand binds, is often observed. The ligand tends to increase its van der Waals or π - π interactions with the β -sheets of the protein, and due to a loss of molecular flexibility, the fluorescence quantum yield increases. The core site (site 3), which is buried inside the protofibril, can often exhibit high affinities for small molecules due to enhanced van der Waals interactions. However, here, we observed a surface site (S4) with strong binding affinities to the negatively charged ligands due to ionic interactions, indicating that the way the fibril twists is crucial for the existence of this site, which is surrounded by several base residues (K43, K45, H50, and K58). In addition to the binding free energies, the residence time of the ligands at the binding sites of the fibrils is also relevant to consider to rank the potency of the ligands, which can be estimated by the dissociation rate constant (k_d) measured with SPR. If a ligand can preferentially bind to the core site(s) inside the protein fibrils, as in the present study, it is usually expected to have stronger binding affinity and longer wash-out time. Several recent studies have suggested the presence of 6 binding sites on A β fibrils [31, 75–79] and at least 4 binding sites on tau fibrils [28, 30, 80, 81]. Kuang et al. showed several surface and 3 core binding sites of PI-2620 [28] on tau fibrils and one core and 3 surface sites on α Syn fibrils [29].

Our affinity data for HS-169 and HS-84 are in line with available binding data for A β ₄₂ fibrils from previous studies. Using SPR, Johansson et al. immobilized azide-functionalized p-FTAA and showed a K_D of ~ 10 nM toward A β ₄₂, as did ratiometric comparison of the excitation spectra for free vs. bound dye [82]. Using competition studies with [³H] X-34, Bäck et al. showed that h-FTAA and q-FTAA bound to recombinant A β ₄₂ fibrils with EC₅₀ values of ~ 250 nM and 330–630 nM, respectively [83]. In addition, Herrmann et al. performed a ratiometric comparison of the excitation spectra for free versus bound dye to determine the K_D values for some LCOs bound to recombinant PrP fibrils, and the K_D values were in the low nM range [84].

Autoradiography and in situ binding assays on brain tissues have also been used for evaluating binding affinity, but in general, only one binding site can be obtained [85]. For fluorescent probes, radiometric analysis has been used to estimate the binding sites with less accuracy. Using radioligand binding assays, multiple ligand binding sites on A β fibrils [17, 86, 87] and tau fibrils [16, 19, 88], e.g., THK-5351 [89], MK-6240 [90], and PBB3 [91], have been reported. Different tau ligands showed distinct binding towards tau in AD and different primary tauopathies [19, 22]. A recent cryo-EM density map revealed that a drug candidate bound to the core site of α Syn [23].

In addition to the affinity information, the rate constants for the different ligands were found to vary by orders of

magnitude for the association, ranging from 10–10⁶ M⁻¹ s⁻¹ and 6 s⁻¹ to 10⁻⁵ s⁻¹ for the association and dissociation steps, respectively (Table 1). Exceptionally small association rate constants were found for some interactions, which are unusually slow, particularly for small molecules. We suggest that low association rate constant may be caused by the inaccessibility of ligands to the core sites, because there is usually a high barrier for ligand to be dissociated from a core site [29]. Therefore, the low affinity of the LCOs for the core site may also be a reason for the observed low association rate constant. There is no contradiction in the slow association and preference of S4. The reason is that a slow association rate constant combines with a slow dissociation rate constant, which results in a higher affinity compared to the other component. A similar slow association was observed by Sevenich et al. for a 16-mer peptide binding to aggregated α Syn [92].

The calculated equilibrium constants K_D are mainly in the nM- μ M range, in agreement with the fact that these dyes have been successfully used in fluorescence imaging applications [8, 72]. Some targets show binding in the low nM range when dissociation is very slow, including α Syn, K18-tau fibrils with h-FTAA and A β ₄₂ fibril with lansoprazol. For the α Syn fibril, it is evident to assign the components found in the analysis of the sensorgrams to the binding sites calculated with molecular mechanics. In such a case, fast binding is expected to occur at sites that are easily accessible, e.g., S1 and S4 in Fig. 4. In contrast, slow association and dissociation components are attributed to core site 3, which is more difficult to access. For K18-tau and A β ₄₂ fibrils, no MM calculations are available. The similarity of the sensorgrams between α Syn suggests that multiple binding sites should also exist in these fibrils. In light of the difficulty in comparing rate constants calculated with higher-order kinetic models, a classification of targets based on the binding properties of the main component may be useful. Basically, there are two types of sensorgrams depending on whether the interaction is governed by a fast (Type 1) or slow (Type 2) association and dissociation (Table 1). In the case of slow dissociation and assuming that the interaction in vivo follows the same kinetics, the ligand is most likely suitable for imaging applications. As a consequence, screening by SPR can be useful for assessing whether a target is suitable for imaging applications. It must be noted that affinities determined at surfaces are typically an order of magnitude, or even more, lower compared with solution measurements.

In addition, similar to the theoretical calculations described here, other studies [84, 93] have shown that the interaction between positively charged lysine residues along the fibrils and the anionic carboxyl groups of the LCOs is crucial for binding. Fibrils are very large molecules and most likely have amine groups that are not part of a binding site.

Since the fibrils are immobilized by the coupling of some of the fibril amine groups to sulfo-NHS-activated carboxylic acid groups on the chip surface, the binding mode of the LCOs might be distorted, as these lysine residues might not be accessible after immobilization. This can only be counteracted by a long linker (in the order of the molecular dimensions of the probe) that increases the distance to the surface or (partly by) a directed immobilization via specific reactive groups, which, as in our case, cannot be realized.

We demonstrated the colocalization of different fluorescence-emitting probes in brain tissue slices from PD patients, α Syn PFF-injected mice, and transgenic mice with A β plaques or tau inclusions, in line with previous observations [55, 68, 94]. The LCOs tested here appear to detect α Syn inclusions in the α Syn PFF-injected mouse brain and can be useful for in vivo imaging studies. Interestingly, we found that these beta-sheet binding chemical probes detected the entire structure of the α Syn deposits, while the pS129- α Syn antibody ab51253 detected mainly the rim of the structure (Fig. 5d), reflected by the low correlation coefficient. This has also been shown in previous studies on α Syn deposits in PD brain tissue slices using another LCO, HS-84 [95], as well as THK-565 (compounds of a different scaffold) [96]. This detection pattern is thus not specific to the q-FTAA. One possible reason is the better penetration of the chemical compounds to the aggregates. Moreover, an earlier study showed that C-terminal posttranslational modifications (PTMs) affect the detection of α Syn pS129 levels in primary neurons [97]. In comparison, chemical probes targeting a beta-sheet structure are less likely to affect the PTM of α Syn.

There are several limitations of our study. First, we did not use brain tissue-derived fibrils from patients with AD, primary tauopathy, PD, or MSA to investigate the ligand binding profiles. The binding sites on recombinant fibrils might differ from those on fibrils derived from patients [98]. Further studies using fibril pulldown from human brain tissue for potential strain-dependent affinity will provide important insight because LCOs have been shown to discriminate α Syn strains in PD and MSA [95, 99]. Second, we did not measure binding to oligomeric forms of A β , tau, or α Syn by SPR due to the uncertainty of the oligomer status on the chips as the fibril rapidly forms. With respect to the fitting of the SPR data, the sum3exp model used to adjust the number of binding sites found in the calculations resulted in low confidence, which was caused by the large number of free fitting parameters. Therefore, it was not reasonable to expect fitting with a sum of 4 exponential kinetic models to lead to useful results. Although most compounds investigated here are fluorescence ligand, we have included drugs such as lansoprazole and methylene blue in this study. The fluorescence ligand is easy to validate in the ex vivo fluorescence staining and colocalization analysis on the brain

tissue. We will assess other PET imaging ligands/drug targeting A-beta/tau/alpha-synuclein in upcoming studies.

Conclusion

In summary, we optimized the SPR assay and performed a systematic evaluation of SPR surfaces to characterize the binding of small molecules to A β ₄₂, K18-tau, full-length 2N4R tau and α Syn fibrils. Moreover, we provided calculation and modeling of the kinetic values of the ligands/drugs on the fibrils with sum3exp kinetic model. The application of this method can greatly improve the efficiency of screening and characterization of imaging ligands/drugs targeting these protein fibrils, which are critical for the diagnosis and treatment of neurodegenerative diseases such as AD, PD, and tauopathies. In addition, such a platform will also be potentially useful for studying competition of binding sites and off-target binding by displacement assays.

Abbreviations AD: Alzheimer's disease; α Syn: Alpha-synuclein; A β : Amyloid-beta; CBD: Corticobasal degeneration; cryo-EM: Cryogenic electron microscopy; GBSA: Generalized born solvent accessibility; HBS: HEPES-buffered saline; hFTAA: Hepta-formylthiophene acetic acid; HS-84: Name of a anionic pentameric oligothiophene; HS-169: Name of a pentameric D-A-D thiophene; k_d : Dissociation rate constant; LCO: Luminescent conjugated oligothiophene; MD: Molecular dynamics; MM: Molecular mechanics; MSA: Multiple system atrophy; PD: Parkinson's disease; PET: Positron emission tomography; PPN: Pedunculopontine nucleus; PSP: Progressive supranuclear palsy; PFF: Preformed fibrils; RMSD: Root-mean-square deviation; qFTAA: Quadro-formylthiophene acetic acid; SPR: Surface plasmon resonance; SNC: Substantia nigra pars compacta; VSGB: Variable dielectric surface generalized born

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00259-024-06806-7>.

Acknowledgements The authors acknowledge the Center for Microscopy and Image Analysis, University of Zurich; Dr. Saroj Kumar Rout, Prof. Jan Klohs, Institute for Biomedical Engineering, ETH Zurich, and Dr. Uwe Roder at Cytiva Europe GmbH.

Authors' contributions The study was designed by RN. JS conducted SPR measurements and kinetic analysis. JL and HA performed and analysed the in silico modelling. JG performed fibril production and fluorescence binding. BC performed staining and confocal microscopy. MH and FG generated the α Syn PFF-injected mouse brains and provided the tissue for immunofluorescence. KPN provided LCOs. JS, JL, HA and RN wrote the first draft. All authors contributed to the revision of the manuscript and approved the final manuscript.

Funding Open access funding provided by University of Zurich. RN received funding from Olga-Mayenfisch Stiftung, Fondation Gustave et Simone Prévot, the Novartis Foundation for Medical-Biological Research, and the Swiss Center for Applied Human Toxicology (SCAHT-AP_22_02). The in silico modeling was enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC 2022-3-34) at the National Supercomputer Centre of Linköping University (Sweden) partially funded by the Swedish Research Council to HÅ (no. 2018-05973).

Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

The preprinted version of the manuscript has been deposited online at Biorxiv [100].

Declarations

Ethics approval and consent to participate All post-mortem human brain tissue had been collected from donors or from whom written informed consent for a brain autopsy and the use of the materials and clinical information for research purposes had been obtained by the NBB. The study was conducted according to the principles of the Declaration of Helsinki and subsequent revisions. All experiments on autopsied human brain tissue were carried out in accordance with ethical permission obtained from the regional human ethics committee in Canton Zurich and the medical ethics committee of the VU Medical Center for the NBB tissue.

For arcA β and pR5 mice, all experiments were performed in accordance with the Swiss Federal Act on Animal Protection and approved by the Cantonal Veterinary Office Zurich (permit number: ZH162/20). For α Syn PFF mice, procedures performed were in accordance with the ethical standards of the institution at which the studies were conducted (Regierungspräsidium Giessen, Germany V54–19c2015h01GI20/28).

Consent to participate Not applicable.

Consent for publication Not applicable.

Competing interests KS and RN are associate editors in Eur J Nucl Med Mol Imaging. RMN is an employee and shareholder of Neurimmune AG, Switzerland. The other authors declare no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. *Nat Neurosci*. 2018;21:1341–9. <https://doi.org/10.1038/s41593-018-0238-6>.
- Spillantini MG, Goedert M. Tau pathology and neurodegeneration. *Lancet Neurol*. 2013;12:609–22. [https://doi.org/10.1016/S1474-4422\(13\)70090-5](https://doi.org/10.1016/S1474-4422(13)70090-5).
- Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. *Lancet Neurol*. 2021;20:484–96. [https://doi.org/10.1016/S1474-4422\(21\)00066-1](https://doi.org/10.1016/S1474-4422(21)00066-1).
- Smith R, Capotosti F, Schain M, Ohlsson T, Touilloux T, Hliva V, et al. Initial clinical scans using [18F]ACI-12589, a novel α -synuclein PET-tracer. *Alzheimers Dement*. 2022;18:e065394. <https://doi.org/10.1002/alz.065394>.
- Xiang J, Tao Y, Xia Y, Luo S, Zhao Q, Li B, et al. Development of an α -synuclein positron emission tomography tracer for imaging synucleinopathies. *Cell*. 2023. <https://doi.org/10.1016/j.cell.2023.06.004>.
- Kuebler L, Buss S, Leonov A, Ryazanov S, Schmidt F, Maurer A, et al. [(11)C]MODAG-001-towards a PET tracer targeting α -synuclein aggregates. *Eur J Nucl Med Mol Imaging*. 2021;48:1759–72. <https://doi.org/10.1007/s00259-020-05133-x>.
- Matsuoka K, Ono M, Takado Y, Hirata K, Endo H, Ohfusa T, et al. High-contrast imaging of α -synuclein pathologies in living patients with multiple system atrophy. *Mov Disord*. 2022;37:2159–61. <https://doi.org/10.1002/mds.29186>.
- Calvo-Rodriguez M, Hou SS, Snyder AC, Dujardin S, Shirani H, Nilsson KPR, et al. In vivo detection of tau fibrils and amyloid beta aggregates with luminescent conjugated oligothiophenes and multiphoton microscopy. *Acta Neuropathol Commun*. 2019;7:171. <https://doi.org/10.1186/s40478-019-0832-1>.
- Verwilt P, Kim H-R, Seo J, Sohn N-W, Cha S-Y, Kim Y, et al. Rational Design of in Vivo Tau Tangle-Selective Near-Infrared Fluorophores: Expanding the BODIPY Universe. *J Am Chem Soc*. 2017;139:13393–403. <https://doi.org/10.1021/jacs.7b05878>.
- Wu Q, Lin Y, Gu J, Sigurdsson E. Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging. *EBioMedicine*. 2018;35. <https://doi.org/10.1016/j.ebiom.2018.08.041>.
- Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, et al. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. *Proc Natl Acad Sci*. 2014;111:510–4. <https://doi.org/10.1073/pnas.1318807111>.
- McMurray L, Macdonald JA, Ramakrishnan NK, Zhao Y, Williamson DW, Tietz O, et al. Synthesis and Assessment of Novel Probes for Imaging Tau Pathology in Transgenic Mouse and Rat Models. *ACS Chem Neurosci*. 2021;12:1885–93. <https://doi.org/10.1021/acscchemneuro.0c00790>.
- Bian J, Liu YQ, He J, Lin X, Qiu CY, Yu WB, et al. Discovery of styrylaniline derivatives as novel alpha-synuclein aggregates ligands. *Eur J Med Chem*. 2021;226:113887. <https://doi.org/10.1016/j.ejmech.2021.113887>.
- Hou SS, Yang J, Lee JH, Kwon Y, Calvo-Rodriguez M, Bao K, et al. Near-infrared fluorescence lifetime imaging of amyloid- β aggregates and tau fibrils through the intact skull of mice. 2023. *Nat Biomed Eng*. <https://doi.org/10.1038/s41551-023-01003-7>.
- Torre-Muruzabal T, Van der Perren A, Coens A, Gelders G, Janer AB, Camacho-Garcia S, et al. Host oligodendroglial pathology and α -synuclein strains dictate disease severity in multiple system atrophy. *Brain*. 2023;146:237–51. <https://doi.org/10.1093/brain/awac061>.
- Malarte ML, Nordberg A, Lemoine L. Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer's disease cases. *Eur J Nucl Med Mol Imaging*. 2020. <https://doi.org/10.1007/s00259-020-05035-y>.
- LeVine H 3rd. Multiple ligand binding sites on A beta(1–40) fibrils. *Amyloid*. 2005;12:5–14. <https://doi.org/10.1080/13506120500032295>.
- Ni R, Gillberg P-G, Bogdanovic N, Viitanen M, Myllykangas L, Nennesmo I, et al. Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. *Alzheimers Dement*. 2017;13:419–30. <https://doi.org/10.1016/j.jalz.2016.08.006>.
- Yap SY, Frias B, Wren MC, Schöll M, Fox NC, Årstad E, et al. Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease. *Brain*. 2021. <https://doi.org/10.1093/brain/awab120>.

20. Gerez JA, Prymaczok NC, Riek R. In-Cell NMR of Intrinsically Disordered Proteins in Mammalian Cells. *Methods Mol Biol.* 2020;2141:873–93. https://doi.org/10.1007/978-1-0716-0524-0_45.
21. Schütz AK, Hornemann S, Wälti MA, Greuter L, Tiberi C, Cadalbert R, et al. Binding of Polythiophenes to Amyloids: Structural Mapping of the Pharmacophore. *ACS Chem Neurosci.* 2018;9:475–81. <https://doi.org/10.1021/acscchemneuro.7b00397>.
22. Shi Y, Murzin A, Falcon B, Epstein A, Machin J, Tempest P, et al. Cryo-EM structures of tau filaments from Alzheimer's disease with PET ligand APN-1607. *Acta Neuropathol.* 2021:1–12. <https://doi.org/10.1007/s00401-021-02294-3>.
23. Antonschmidt L, Matthes D, Dervişoğlu R, Frieg B, Diemann C, Leonov A, et al. The clinical drug candidate anle138b binds in a cavity of lipidic α -synuclein fibrils. *Nat Commun.* 2022;13:5385. <https://doi.org/10.1038/s41467-022-32797-w>.
24. Ferrie JJ, Lengyel-Zhand Z, Janssen B, Lougee MG, Giannakoulas S, Hsieh C-J, et al. Identification of a nanomolar affinity α -synuclein fibril imaging probe by ultra-high throughput in silico screening. *Chem Sci.* 2020;11:12746–54. <https://doi.org/10.1039/d0sc02159h>.
25. Sanna E, Rodrigues M, Fagan SG, Chisholm TS, Kulenkampff K, Klenerman D, et al. Mapping the binding site topology of amyloid protein aggregates using multivalent ligands. *Chem Sci.* 2021;12:8892–9. <https://doi.org/10.1039/d1sc01263k>.
26. Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, et al. Structure-based classification of tauopathies. *Nature.* 2021. <https://doi.org/10.1038/s41586-021-03911-7>.
27. Zhou Y, Li J, Nordberg A, Ågren H. Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils. *ACS Chem Neurosci.* 2021;12:3487–96. <https://doi.org/10.1021/acscchemneuro.1c00536>.
28. Kuang G, Murugan NA, Zhou Y, Nordberg A, Ågren H. Computational Insight into the Binding Profile of the Second-Generation PET Tracer PI2620 with Tau Fibrils. *ACS Chem Neurosci.* 2020;11:900–8. <https://doi.org/10.1021/acscchemneuro.9b00578>.
29. Kuang G, Murugan NA, Ågren H. Mechanistic Insight into the Binding Profile of DCVJ and α -Synuclein Fibril Revealed by Multiscale Simulations. *ACS Chem Neurosci.* 2019;10:610–7. <https://doi.org/10.1021/acscchemneuro.8b00465>.
30. Murugan NA, Nordberg A, Ågren H. Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling. *ACS Chem Neurosci.* 2018;9:1757–67. <https://doi.org/10.1021/acscchemneuro.8b00093>.
31. Murugan NA, Halldin C, Nordberg A, Långström B, Ågren H. The Culprit Is in the Cave: The Core Sites Explain the Binding Profiles of Amyloid-Specific Tracers. *J Phys Chem Lett.* 2016;7:3313–21. <https://doi.org/10.1021/acs.jpcclett.6b01586>.
32. Karlsson R. SPR for molecular interaction analysis: a review of emerging application areas. *J Mol Recognit.* 2004;17:151–61. <https://doi.org/10.1002/jmr.660>.
33. Erbaş A, İnci F. The Role of Ligand Rebinding and Facilitated Dissociation on the Characterization of Dissociation Rates by Surface Plasmon Resonance (SPR) and Benchmarking Performance Metrics. *Methods Mol Biol.* 2022;2385:237–53. https://doi.org/10.1007/978-1-0716-1767-0_11.
34. Nangare S, Patil P. Nanoarchitected Bioconjugates and Bio-receptors Mediated Surface Plasmon Resonance Biosensor for In Vitro Diagnosis of Alzheimer's Disease: Development and Future Prospects. *Crit Rev Anal Chem.* 2021:1–31. <https://doi.org/10.1080/10408347.2020.1864716>.
35. Rezabakhsh A, Rahbarghazi R, Fathi F. Surface plasmon resonance biosensors for detection of Alzheimer's biomarkers; an effective step in early and accurate diagnosis. *Biosens Bioelectron.* 2020;167:112511. <https://doi.org/10.1016/j.bios.2020.112511>.
36. Stravalaci M, Bastone A, Beeg M, Cagnotto A, Colombo L, Di Fede G, et al. Specific recognition of biologically active amyloid- β oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in *Caenorhabditis elegans*. *J Biol Chem.* 2012;287:27796–805. <https://doi.org/10.1074/jbc.M111.334979>.
37. Kim S, Wark AW, Lee HJ. Femtomolar Detection of Tau Proteins in Undiluted Plasma Using Surface Plasmon Resonance. *Anal Chem.* 2016;88:7793–9. <https://doi.org/10.1021/acs.analchem.6b01825>.
38. Ryu J, Joung HA, Kim MG, Park CB. Surface plasmon resonance analysis of Alzheimer's beta-amyloid aggregation on a solid surface: from monomers to fully-grown fibrils. *Anal Chem.* 2008;80:2400–7. <https://doi.org/10.1021/ac7019514>.
39. Stravalaci M, Beeg M, Salmona M, Gobbi M. Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic A β (1–42) peptide, synthesized by depsi-peptide technique. *Biosens Bioelectron.* 2011;26:2772–5. <https://doi.org/10.1016/j.bios.2010.10.038>.
40. Dehghani M, Jalal R, Rashidi MR. Kinetic and thermodynamic insights into the interaction of A β 1-42 with astaxanthin and aggregation behavior of A β 1-42: Surface plasmon resonance, microscopic, and molecular docking studies. *Biophys Chem.* 2021;275:106612. <https://doi.org/10.1016/j.bpc.2021.106612>.
41. Marasco D, Vicidomini C, Krupa P, Cioffi F, Huy PDQ, Li MS, et al. Plant isoquinoline alkaloids as potential neurodrugs: A comparative study of the effects of benzo[c]phenanthridine and berberine-based compounds on β -amyloid aggregation. *Chem Biol Interact.* 2021;334:109300. <https://doi.org/10.1016/j.cbi.2020.109300>.
42. De Simone A, Mancini F, Real Fernández F, Rovero P, Bertucci C, Andrisano V. Surface plasmon resonance, fluorescence, and circular dichroism studies for the characterization of the binding of BACE-1 inhibitors. *Anal Bioanal Chem.* 2013;405:827–35. <https://doi.org/10.1007/s00216-012-6312-0>.
43. Frenzel D, Glück JM, Brener O, Oesterhelt F, Nagel-Steger L, Willbold D. Immobilization of homogeneous monomeric, oligomeric and fibrillar A β species for reliable SPR measurements. *PLoS ONE.* 2014;9:e89490. <https://doi.org/10.1371/journal.pone.0089490>.
44. Jha NN, Kumar R, Panigrahi R, Navalkar A, Ghosh D, Sahay S, et al. Comparison of α -Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors. *ACS Chem Neurosci.* 2017;8:2722–33. <https://doi.org/10.1021/acscchemneuro.7b00261>.
45. Honarmand S, Dabirmanesh B, Amanlou M, Khajeh K. The interaction of several herbal extracts with α -synuclein: Fibril formation and surface plasmon resonance analysis. *PLoS One.* 2019;14:e0217801. <https://doi.org/10.1371/journal.pone.0217801>.
46. Thom T, Schmitz M, Fischer AL, Correia A, Correia S, Llorens F, et al. Cellular prion protein mediates α -synuclein uptake, localization, and toxicity in vitro and in vivo. *Mov Disord.* 2021. <https://doi.org/10.1002/mds.28774>.
47. Yin Z, Cheng X, Wang G, Chen J, Jin Y, Tu Q, et al. SPR immunosensor combined with Ti(4+)-TiP nanoparticles for the evaluation of phosphorylated alpha-synuclein level. *Mikrochim Acta.* 2020;187:509. <https://doi.org/10.1007/s00604-020-04507-0>.
48. Sangwan S, Sahay S, Murray KA, Morgan S, Guenther EL, Jiang L, et al. Inhibition of synucleinopathic seeding by rationally designed inhibitors. *Elife.* 2020;9. <https://doi.org/10.7554/eLife.46775>.
49. Lisi S, Scarano S, Fedeli S, Pascale E, Cicchi S, Ravelet C, et al. Toward sensitive immuno-based detection of tau protein by

- surface plasmon resonance coupled to carbon nanostructures as signal amplifiers. *Biosens Bioelectron.* 2017;93:289–92. <https://doi.org/10.1016/j.bios.2016.08.078>.
50. Haghaei H, Aref Hosseini SR, Soltani S, Fathi F, Mokhtari F, Karima S, et al. Kinetic and thermodynamic study of beta-Boswellic acid interaction with Tau protein investigated by surface plasmon resonance and molecular modeling methods. *Bioimpacts.* 2020;10:17–25. <https://doi.org/10.15171/bi.2020.03>.
 51. Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. *J Alzheimers Dis.* 2010;19:573–89. <https://doi.org/10.3233/JAD-2010-1262>.
 52. Martins AF, Dias DM, Morfin J-F, Lacerda S, Laurents DV, Tóth É, et al. Interaction of PiB-derivative metal complexes with beta-amyloid peptides: Selective recognition of the aggregated forms. *Chem Eur J.* 2015;21:5413–22. <https://doi.org/10.1002/chem.201406152>.
 53. Burmann BM, Gerez JA, Matecko-Burmann I, Campioni S, Kumari P, Ghosh D, et al. Regulation of alpha-synuclein by chaperones in mammalian cells. *Nature.* 2019. <https://doi.org/10.1038/s41586-019-1808-9>.
 54. Gerez JA, Prymaczek NC, Rockenstein E, Herrmann US, Schwarz P, Adame A, et al. A cullin-RING ubiquitin ligase targets exogenous alpha-synuclein and inhibits Lewy body-like pathology. *Sci Transl Med.* 2019;11. <https://doi.org/10.1126/scitranslmed.aau6722>.
 55. Ni R, Chen Z, Gerez JA, Shi G, Zhou Q, Riek R, et al. Detection of cerebral tauopathy in P301L mice using high-resolution large-field multifocal illumination fluorescence microscopy. *Biomed Opt Express.* 2020;11:4989–5002. <https://doi.org/10.1364/boe.395803>.
 56. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG. Analyzing a kinetic titration series using affinity biosensors. *Anal Biochem.* 2006;349:136–47. <https://doi.org/10.1016/j.ab.2005.09.034>.
 57. Guerrero-Ferreira R, Taylor NMI, Mona D, Ringler P, Lauer ME, Riek R, et al. Cryo-EM structure of alpha-synuclein fibrils. *eLife.* 2018;7:e36402. <https://doi.org/10.7554/eLife.36402>.
 58. Kumari P, Ghosh D, Vanas A, Fleischmann Y, Wiegand T, Jeschke G, et al. Structural insights into α -synuclein monomer-fibril interactions. *Proc Natl Acad Sci USA.* 2021;118. <https://doi.org/10.1073/pnas.2012171118>.
 59. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A New Approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J Med Chem.* 2004;47:1739–49. <https://doi.org/10.1021/jm0306430>.
 60. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. *J Med Chem.* 2004;47:1750–9. <https://doi.org/10.1021/jm030644s>.
 61. Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W, et al. OPLS4: Improving force field accuracy on challenging regimes of chemical space. *J Chem Theory Comput.* 2021;17:4291–300. <https://doi.org/10.1021/acs.jctc.1c00302>.
 62. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. *J Chem Phys.* 1983;79:926–35. <https://doi.org/10.1063/1.445869>.
 63. Martyna GJ, Klein ML, Tuckerman M. Nosé-Hoover chains: The canonical ensemble via continuous dynamics. *J Chem Phys.* 1992;97:2635–43. <https://doi.org/10.1063/1.463940>.
 64. Martyna GJ, Tobias DJ, Klein ML. Constant pressure molecular dynamics algorithms. *J Chem Phys.* 1994;101:4177–89. <https://doi.org/10.1063/1.467468>.
 65. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, et al. Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. *Acc Chem Res.* 2000;33:889–97. <https://doi.org/10.1021/ar00033j>.
 66. Li J, Abel R, Zhu K, Cao Y, Zhao S, Friesner RA. The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. *Proteins Struct Funct Bioinform.* 2011;79:2794–812. <https://doi.org/10.1002/prot.23106>.
 67. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular A β and cognitive deficits precede β -amyloid deposition in transgenic arcA β mice. *Neurobiol Aging.* 2007;28:1297–306. <https://doi.org/10.1016/j.neurobiolaging.2006.06.019>.
 68. Ren W, Li L, Zhang J, Vaas M, Klohs J, Ripoll J, et al. Non-invasive visualization of amyloid-beta deposits in Alzheimer amyloidosis mice using magnetic resonance imaging and fluorescence molecular tomography. *Biomed Opt Express.* 2022;13:3809–22. <https://doi.org/10.1364/boe.458290>.
 69. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. *Science.* 2001;293:1491–5. <https://doi.org/10.1126/science.1062097>.
 70. Henrich MT, Geibl FF, Lakshminarasimhan H, Stegmann A, Giasson BI, Mao X, et al. Determinants of seeding and spreading of α -synuclein pathology in the brain. *Sci Adv.* 2020;6. <https://doi.org/10.1126/sciadv.abc2487>.
 71. Henrich MT, Geibl FF, Lee B, Chiu WH, Koprach JB, Brotchie JM, et al. A53T- α -synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. *Acta Neuropathol Commun.* 2018;6:39. <https://doi.org/10.1186/s40478-018-0541-1>.
 72. Ni R, Chen Z, Deán-Ben XL, Voigt FF, Kirschenbaum D, Shi G, et al. Multiscale optical and optoacoustic imaging of amyloid- β deposits in mice. *Nat Biomed Eng.* 2022. <https://doi.org/10.1038/s41551-022-00906-1>.
 73. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. *Sci Rep.* 2017;7:16878. <https://doi.org/10.1038/s41598-017-17204-5>.
 74. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods.* 2012;9:676–82. <https://doi.org/10.1038/nmeth.2019>.
 75. Arul Murugan N, Zaleśny R, Ågren H. Unusual binding-site-specific photophysical properties of a benzothiazole-based optical probe in amyloid beta fibrils. *Phys Chem Chem Phys.* 2018;20:20334–9. <https://doi.org/10.1039/c8cp03274b>.
 76. Balamurugan K, Murugan NA, Långström B, Nordberg A, Ågren H. Effect of Alzheimer familial chromosomal mutations on the amyloid fibril interaction with different PET tracers: Insight from molecular modeling studies. *ACS Chem Neurosci.* 2017;8:2655–66. <https://doi.org/10.1021/acscchemneuro.7b00215>.
 77. Kuang G, Murugan NA, Tu Y, Nordberg A, Ågren H. Investigation of the binding profiles of AZD2184 and thioflavin T with amyloid- β (1–42) fibril by molecular docking and molecular dynamics methods. *J Phys Chem B.* 2015;119:11560–7. <https://doi.org/10.1021/acs.jpcc.5b05964>.
 78. Murugan NA, Zaleśny R, Kongsted J, Nordberg A, Ågren H. Promising two-photon probes for in vivo detection of β amyloid deposits. *Chem Commun (Camb).* 2014;50:11694–7. <https://doi.org/10.1039/c4cc03897e>.

79. Kawai R, Araki M, Yoshimura M, Kamiya N, Ono M, Saji H, et al. Core binding site of a thioflavin-T-derived imaging probe on amyloid β fibrils predicted by computational methods. *ACS Chem Neurosci*. 2018;9:957–66. <https://doi.org/10.1021/acscchemneuro.7b00389>.
80. Murugan NA, Nordberg A, Ågren H. Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy. *ACS Chem Neurosci*. 2021. <https://doi.org/10.1021/acscchemneuro.0c00340>.
81. Murugan NA, Chiotis K, Rodriguez-Vieitez E, Lemoine L, Ågren H, Nordberg A. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. *Eur J Nucl Med Mol Imaging*. 2019;46:1369–82. <https://doi.org/10.1007/s00259-019-04305-8>.
82. Johansson LBG, Simon R, Bergström G, Eriksson M, Prokop S, Mandenius CF, et al. An azide functionalized oligothiophene ligand—a versatile tool for multimodal detection of disease associated protein aggregates. *Biosens Bioelectron*. 2015;63:204–11. <https://doi.org/10.1016/j.bios.2014.07.042>.
83. Bäck M, Appelqvist H, LeVine H 3rd, Nilsson KP. Anionic Oligothiophenes Compete for Binding of X-34 but not PIB to Recombinant A β Amyloid Fibrils and Alzheimer's Disease Brain-Derived A β . *Chemistry*. 2016;22:18335–8. <https://doi.org/10.1002/chem.201604583>.
84. Herrmann Uli S, Schütz Anne K, Shirani H, Huang D, Saban D, Nuvolone M, et al. Structure-based drug design identifies polythiophenes as antiprion compounds. *Sci Transl Med*. 2015;7:299ra123–299ra123. <https://doi.org/10.1126/scitranslmed.aab1923>.
85. Han BH, Zhou M-L, Vellimana AK, Milner E, Kim DH, Greenberg JK, et al. Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. *Mol Neurodegener*. 2011;6:86. <https://doi.org/10.1186/1750-1326-6-86>.
86. Ni R, Röjdner J, Voytenko L, Dyrks T, Thiele A, Marutle A, et al. In vitro characterization of the regional binding distribution of amyloid PET tracer florbetaben and the glia tracers deprenyl and PK11195 in autopsy Alzheimer's brain tissue. *J Alzheimers Dis*. 2021;80:1723–37. <https://doi.org/10.3233/jad-201344>.
87. Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. *Brain*. 2013;136:2217–27. <https://doi.org/10.1093/brain/awt142>.
88. Ni R, Ji B, Ono M, Sahara N, Zhang MR, Aoki I, et al. Comparative in-vitro and in-vivo quantifications of pathological tau deposits and their association with neurodegeneration in tauopathy mouse models. *J Nucl Med*. 2018;59:960–6. <https://doi.org/10.2967/jnumed.117.201632>.
89. Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. *Alzheimers Res Ther*. 2017;9:96. <https://doi.org/10.1186/s13195-017-0325-z>.
90. Malarte ML, Gillberg PG, Kumar A, Bogdanovic N, Lemoine L, Nordberg A. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains. *Mol Psychiatry*. 2022. <https://doi.org/10.1038/s41380-022-01875-2>.
91. Ono M, Sahara N, Kumata K, Ji B, Ni R, Koga S, et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. *Brain*. 2017;140:764–80. <https://doi.org/10.1093/brain/aww339>.
92. Sevenich M, Honold D, Willuweit A, Kutzsche J, Mohrlüder J, Willbold D. Development of an α -synuclein fibril and oligomer specific tracer for diagnosis of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. *Neurochem Int*. 2022;161:105422. <https://doi.org/10.1016/j.neuint.2022.105422>.
93. König C, Skånberg R, Hotz I, Ynnerman A, Norman P, Linares M. Binding sites for luminescent amyloid biomarkers from non-biased molecular dynamics simulations. *Chem Commun (Camb)*. 2018;54:3030–3. <https://doi.org/10.1039/c8cc00105g>.
94. Ni R, Villosio A, Dean-Ben XL, Chen Z, Vaas M, Stavrakis S, et al. In-vitro and in-vivo characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice. *Photoacoustics*. 2021;23:100285. <https://doi.org/10.1016/j.pacs.2021.100285>.
95. Klingstedt T, Ghetti B, Holton JL, Ling H, Nilsson KPR, Goedert M. Luminescent conjugated oligothiophenes distinguish between α -synuclein assemblies of Parkinson's disease and multiple system atrophy. *Acta Neuropathol Commun*. 2019;7:193. <https://doi.org/10.1186/s40478-019-0840-1>.
96. Straumann N, Combes BF, Dean-Ben XL, Steerke R, Gerez J, Dias I, et al. Visualizing alpha-synuclein and iron deposition in M83 mouse model of Parkinson's disease in vivo. *bioRxiv*. 2023. <https://doi.org/10.1101/2023.06.28.546962>.
97. Lashuel HA, Mahul-Mellier AL, Novello S, Hegde RN, Jasiqi Y, Altay MF, et al. Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity. *NPJ Parkinsons Dis*. 2022;8:136. <https://doi.org/10.1038/s41531-022-00388-7>.
98. Lövestam S, Schweighauser M, Matsubara T, Murayama S, Tomita T, Ando T, et al. Seeded assembly in vitro does not replicate the structures of α -synuclein filaments from multiple system atrophy. *FEBS Open Bio*. 2021;11:999–1013. <https://doi.org/10.1002/2211-5463.13110>.
99. Shah Nawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating α -synuclein strains in Parkinson's disease and multiple system atrophy. *Nature*. 2020;578:273–7. <https://doi.org/10.1038/s41586-020-1984-7>.
100. Sobek J, Li J, Combes BF, Gerez JA, Nilsson PK, Henrich MT, et al. Efficient characterization of multiple binding sites of small molecule imaging ligands on amyloid-beta, 4-repeat/full-length tau and alpha-synuclein. *bioRxiv*. 2023. <https://doi.org/10.1101/2023.03.12.531651>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.